STOCK TITAN

Relay Therapeutics: SoftBank reports 9.9% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Relay Therapeutics, Inc. (RLAY) was the issuer for which SB Investment Advisers (UK) Limited, SoftBank Vision Fund (AIV M2) L.P., and SVF Pauling (Cayman) Limited reported shared beneficial ownership of 21,904,963 shares, or 9.9% of the common stock, as of September 30, 2026. The ownership figure was based on 220,959,470 common shares outstanding as of October 30, 2026.

Shared beneficial ownership 21,904,963 shares Reported by each reporting person as of September 30, 2026
Percentage of class 9.9% Reported beneficial ownership as of September 30, 2026
Common shares outstanding 220,959,470 shares As of October 30, 2026
beneficial ownership regulatory
"Amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
alternative investment fund manager regulatory
"SBIA UK has been appointed as alternative investment fund manager"
An alternative investment fund manager is a firm or individual that runs pooled investment vehicles that buy non-traditional assets—such as private equity, hedge funds, real estate, commodities or infrastructure—rather than publicly traded stocks and bonds. Investors care because these managers seek higher or different types of returns and risks, charge specialized fees, and often use less liquid strategies, so they can materially affect portfolio risk, return and access to opportunities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Relay Therapeutics (RLAY) shares did the reporting persons beneficially own?

The three reporting persons each reported shared beneficial ownership of 21,904,963 shares, equal to 9.9% of the common stock, as of September 30, 2026.

Who holds the Relay Therapeutics shares reported by SoftBank?

SVF Pauling (Cayman) Limited is the record holder and is a wholly owned subsidiary of SoftBank Vision Fund (AIV M2) L.P. SB Investment Advisers (UK) Limited was appointed as the fund’s alternative investment fund manager and is exclusively responsible for decisions related to its investments, including voting and disposal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





75943R102

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



SB Investment Advisers (UK) Limited
Signature:/s/ Amanda Sanchez-Barry
Name/Title:Amanda Sanchez-Barry, General Counsel
Date:11/16/2026
SoftBank Vision Fund (AIV M2) L.P.
Signature:By: SB Investment Advisers (UK) Limited, its manager, By: /s/ Amanda Sanchez-Barry
Name/Title:Amanda Sanchez-Barry, General Counsel
Date:11/16/2026
SVF Pauling (Cayman) Ltd
Signature:By: /s/ Nilani Perera
Name/Title:Nilani Perera, Director
Date:11/16/2026
Exhibit Information

Exhibit 99: Joint Filing Agreement (previously filed).

Keep reading